[go: up one dir, main page]

SG11202009103WA - Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 - Google Patents

Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Info

Publication number
SG11202009103WA
SG11202009103WA SG11202009103WA SG11202009103WA SG11202009103WA SG 11202009103W A SG11202009103W A SG 11202009103WA SG 11202009103W A SG11202009103W A SG 11202009103WA SG 11202009103W A SG11202009103W A SG 11202009103WA SG 11202009103W A SG11202009103W A SG 11202009103WA
Authority
SG
Singapore
Prior art keywords
inhibitors
cannabinoid receptor
pyrazine compounds
novel pyridine
pyridine
Prior art date
Application number
SG11202009103WA
Inventor
Luca Gobbi
Uwe Grether
Julian Kretz
Simon Ametamey
Original Assignee
Hoffmann La Roche
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Eth Zuerich filed Critical Hoffmann La Roche
Publication of SG11202009103WA publication Critical patent/SG11202009103WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
SG11202009103WA 2018-06-27 2019-06-25 Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 SG11202009103WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180137 2018-06-27
PCT/EP2019/066811 WO2020002320A1 (en) 2018-06-27 2019-06-25 Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Publications (1)

Publication Number Publication Date
SG11202009103WA true SG11202009103WA (en) 2020-10-29

Family

ID=62814868

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009103WA SG11202009103WA (en) 2018-06-27 2019-06-25 Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Country Status (19)

Country Link
US (2) US12071420B2 (en)
EP (1) EP3814329B1 (en)
JP (1) JP7445610B2 (en)
KR (1) KR102790077B1 (en)
CN (2) CN112262132A (en)
AU (2) AU2019294256B2 (en)
BR (1) BR112020025013A2 (en)
CA (1) CA3096777A1 (en)
CL (1) CL2020003331A1 (en)
CO (1) CO2020011855A2 (en)
CR (1) CR20200643A (en)
IL (1) IL279725B2 (en)
MA (1) MA53002A (en)
MX (1) MX2020012760A (en)
PE (1) PE20210368A1 (en)
PH (1) PH12020552152A1 (en)
SG (1) SG11202009103WA (en)
WO (1) WO2020002320A1 (en)
ZA (1) ZA202005426B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030671B4 (en) 2006-07-04 2008-10-02 Moeller Gmbh Breaker short-O combination
AR112199A1 (en) 2017-06-20 2019-10-02 Hoffmann La Roche PYRIDINE DERIVATIVES AS INVERSE AGONISTS OF CANNABINOID RECEPTOR 2
SG11202009103WA (en) 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020002314A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Radiolabeled cannabinoid receptor 2 ligand
EP3814337B1 (en) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
EP4423256A2 (en) 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430747T2 (en) 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling CONNECTIONS AS PDE IV AND TNF INHIBITORS
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE407119T1 (en) * 2004-02-24 2008-09-15 Glaxo Group Ltd PYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF THE CB2 RECEPTOR
GB0418047D0 (en) 2004-08-12 2004-09-15 Syngenta Participations Ag Fungicidal compositions
CA2601575A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
FR2887550A1 (en) 2005-06-24 2006-12-29 Sanofi Aventis Sa New 1-benzylpyrazole-3-acetamide compounds are cannabinoids receptor antagonists useful to treat/prevent immune disorders, pain, gastrointestinal disturbances, cardiovascular/kidney disorders and in cancer chemotherapy
US8710233B2 (en) 2005-10-19 2014-04-29 Gruenenthal Gmbh Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations
ES2344128T3 (en) * 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag DERIVATIVES OF PIRAZINA-2-CARBOXAMIDE AS CB2 RECEIVER MODULATORS.
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
ME02419B (en) 2011-08-25 2016-09-20 Merck Sharp & Dohme PDE10 PYRIMIDININHIBITOREN
US9403808B2 (en) 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
WO2014071361A1 (en) 2012-11-05 2014-05-08 Rubicon Genomics Barcoding nucleic acids
CA2885987A1 (en) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
CN104837831B (en) 2012-12-07 2017-10-31 霍夫曼-拉罗奇有限公司 new pyridine derivatives
US9512141B2 (en) 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
RS56424B1 (en) 2012-12-07 2018-01-31 Hoffmann La Roche PIRIDIN-2-AMIDES USEFUL AS CB2-AGONISTS
NO2978755T3 (en) 2013-03-26 2018-06-02
SG11201608246VA (en) * 2014-04-04 2016-10-28 Hoffmann La Roche 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
MA39843A (en) 2014-04-04 2017-02-08 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
CN106795121A (en) 2014-10-27 2017-05-31 豪夫迈·罗氏有限公司 The part of radioactive label Cannabined receptor 2
JO3705B1 (en) 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
PE20181203A1 (en) 2015-12-09 2018-07-23 Hoffmann La Roche PHENYL DERIVATIVES AS CANNABINOID 2 RECEPTOR AGONISTS
ES3002386T3 (en) 2017-03-23 2025-03-06 Univ Washington Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing
TW201906818A (en) 2017-05-31 2019-02-16 美商５１１製藥公司 Novel erbium-substituted positron emission tomography (PET) developer and its pharmacological application
AR112199A1 (en) 2017-06-20 2019-10-02 Hoffmann La Roche PYRIDINE DERIVATIVES AS INVERSE AGONISTS OF CANNABINOID RECEPTOR 2
GEAP202215479A (en) 2018-05-15 2022-06-10 H Lundbeck As Magl inhibitors
WO2020002314A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Radiolabeled cannabinoid receptor 2 ligand
SG11202009103WA (en) 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814337B1 (en) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
TWI687701B (en) 2018-12-05 2020-03-11 宏碁股份有限公司 Method for determining state of charge and electronic device thereof

Also Published As

Publication number Publication date
US20240383872A1 (en) 2024-11-21
AU2024219640A1 (en) 2024-10-03
US20210115011A1 (en) 2021-04-22
IL279725B1 (en) 2023-12-01
IL279725A (en) 2021-03-01
JP2021529157A (en) 2021-10-28
MX2020012760A (en) 2021-03-25
CL2020003331A1 (en) 2021-05-07
CN112262132A (en) 2021-01-22
PH12020552152A1 (en) 2021-07-05
PE20210368A1 (en) 2021-02-26
CR20200643A (en) 2021-05-11
IL279725B2 (en) 2024-04-01
EP3814329A1 (en) 2021-05-05
CO2020011855A2 (en) 2020-10-20
EP3814329B1 (en) 2024-01-17
CA3096777A1 (en) 2020-02-02
US12071420B2 (en) 2024-08-27
CN119161323A (en) 2024-12-20
BR112020025013A2 (en) 2021-03-23
AU2019294256A1 (en) 2020-09-24
EP3814329C0 (en) 2024-01-17
WO2020002320A1 (en) 2020-01-02
ZA202005426B (en) 2025-06-25
KR102790077B1 (en) 2025-04-03
MA53002A (en) 2021-05-05
KR20210028202A (en) 2021-03-11
JP7445610B2 (en) 2024-03-07
AU2019294256B2 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
IL279725A (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
IL266214A (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
IL268031B (en) Pyridine compounds as allosteric shp2 inhibitors
IL263163A (en) Substituted pyridines as inhibitors of dnmt1
IL260448B (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
SMT202400385T1 (en) Novel heterocyclic derivatives useful as shp2 inhibitors
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
IL246436A0 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
MX383935B (en) Heterocyclic amides as kinase inhibitors
SG11202010679SA (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
EP3615657A4 (en) Apparatus, methods and composition for synthesis of cannabinoid compounds
PL3621615T3 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EP3697791A4 (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
HUE068098T2 (en) Method for synthesis of eliglustat and intermediate compounds thereof
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL290137A (en) Application of polypeptide or derivative thereof
IL276887A (en) Chromene derivatives as inhibitors of tcr-nck interaction
PL3752129T3 (en) The multifunctional composition of torasemide
EP3275882A4 (en) Process of synthesizing substituted pyridine and pyrimidine compound
IL266121A (en) Substituted quinoxaline derivatives as inhibitors of pfkfb
PL3339397T3 (en) The fire-resistant composition and the method of its production, and the insulation product containing the fire-resistant composition and the method of its production
HK40036936A (en) (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
HK1262425A1 (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
GB201820685D0 (en) Synthesis of 8-chloroadenosine derivatives